公开(公告)号：US09944596B2

公开(公告)日：2018-04-17

申请号：US15518782

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Takahiko Taniguchi ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D207/08 ,  A61K31/401

CPC classification number: C07D207/08 ,  A61K31/40 ,  A61K31/401 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US12024505B2

公开(公告)日：2024-07-02

申请号：US18081395

申请日：2022-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu Sasaki ,  Masaki Seto ,  Kazuaki Takami ,  Haruhi Ando

IPC: C07D405/14 ,  A61P1/10 ,  C07D405/04 ,  C07D409/14

CPC classification number: C07D405/14 ,  A61P1/10 ,  C07D405/04 ,  C07D409/14

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I):




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10807987B2

公开(公告)日：2020-10-20

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20200157062A1

公开(公告)日：2020-05-21

申请号：US16773720

申请日：2020-01-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasak

IPC: C07D263/46 ,  C07D213/70 ,  A61P27/02 ,  C07D213/65 ,  C07D263/38 ,  C07D239/34 ,  C07D231/22 ,  C07D231/12 ,  A61K31/505 ,  A61K31/4418 ,  A61K31/421 ,  A61K31/415

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US10214498B2

公开(公告)日：2019-02-26

申请号：US15517227

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: A61P27/02 ,  C07K14/47 ,  C12N15/09 ,  A61K31/415 ,  A61K31/505 ,  C07D213/65 ,  C07D213/70 ,  C07D231/12 ,  C07D231/22 ,  C07D239/34 ,  A61K31/4418 ,  A61K31/421 ,  C07D263/38 ,  C07D263/46

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US09321757B2

公开(公告)日：2016-04-26

申请号：US14533326

申请日：2014-11-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki Takami ,  Yusuke Tominari ,  Zenyu Shiokawa ,  Akito Shibuya ,  Yusuke Sasaki ,  Tony Gibson ,  Terufumi Takagi

IPC: C07D401/14 ,  C07D487/04 ,  C07D417/14 ,  C07D487/10 ,  A61P37/00 ,  C07D403/14 ,  A61K31/4155 ,  C07D413/14 ,  C07D409/14 ,  C07D405/14 ,  C07D401/04 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物，其可用于预防或治疗炎性疾病，自身免疫性疾病，骨关节炎性退行性疾病，肿瘤性疾病等，以及含有它们的药物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US11970483B2

公开(公告)日：2024-04-30

申请号：US17280633

申请日：2019-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinobu Sasaki ,  Yasutomi Asano ,  Kazuaki Takami ,  Masaki Seto ,  Haruhi Ando

IPC: C07D405/14 ,  A61P1/10 ,  C07D407/12 ,  C07D407/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D405/14 ,  A61P1/10 ,  C07D407/12 ,  C07D407/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I):




wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and ring A is an optionally further substituted ring, or a salt thereof.

公开(公告)号：US11702419B2

公开(公告)日：2023-07-18

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

CPC classification number: C07D487/04 ,  A61K9/2095 ,  A61K9/4833 ,  A61P25/00 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20210340114A1

公开(公告)日：2021-11-04

申请号：US17226854

申请日：2021-04-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  A61K31/4418 ,  A61P27/02 ,  A61K31/421 ,  C07D231/22 ,  C07D239/34 ,  A61K31/505 ,  C07D263/38 ,  C07D213/70 ,  C07D213/65 ,  C07D231/12 ,  A61K31/415 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US10544111B2

公开(公告)日：2020-01-28

申请号：US16230634

申请日：2018-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/505 ,  C07D231/12 ,  C07D231/22 ,  C07D239/34 ,  C07D263/38 ,  C07D213/65 ,  A61P27/02 ,  C07D213/70 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.